A greener approach towards double heteroarylation of N, O and S nucleophiles: synthesis of bioactive polynuclear fused N-heteroarenes

Satish P. Nikumbhab, Akula Raghunadha, V. Narayana Murthya, Rajesh Jinkalaa, Suju C. Josephab, Y. L. N. Murthyb, Bagineni Prasadc and Manojit Pal*c
aTechnology Development Centre, Custom Pharmaceutical Services, Dr Reddy's Laboratories Ltd, Hyderabad 500049, India
bDepartment of Organic Chemistry, Andhra University, Visakhapatnam 530003, India
cDr Reddy's Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500 046, India. E-mail: manojitpal@rediffmail.com; Tel: +91 40 6657 1500

Received 31st July 2015 , Accepted 24th August 2015

First published on 24th August 2015


Abstract

A catalyst, ligand and solvent free method for double heteroarylation of N, O and S nucleophiles has been developed for the first time leading towards the synthesis of compounds containing an indole ring fused with pyrrolo-, furo- and thieno[2,3-b]quinoxaline moieties. This general and greener approach afforded novel compounds of medicinal importance.


Polynuclear fused N-heteroarenes are attractive templates for the discovery and development of new bioactive molecules and drugs. For example, the indolo[3,2-e][1,2,3]triazolo[1,5-a]pyrimidine scaffold has been used for the identification of potent antitumor agents.1 Likewise, the indolo[2,3-b]quinoxaline2 framework has been used for the identification of anti-viral (e.g. B-220, Fig. 1)2a and anti-tumor agents (e.g. NCA0424 and NCA0465, Fig. 1).2b Additionally, polynuclear fused N-heteroarenes can be realized by introducing conformational restriction to their flexible parent molecules as this strategy could provide valuable insights regarding the interaction of the precursory flexible molecule with the putative receptor or enzyme.2c All these reports and our continuing interest in quinoxaline derivatives3 prompted us to explore indolo[3′,2′:4,5]pyrrolo-, indolo[3′,2′:4,5]furo- and indolo[3′,2′:4,5]thieno[2,3-b]quinoxaline derivatives represented by A (Fig. 2) as potential and novel antiproliferative agents.
image file: c5ra16727b-f1.tif
Fig. 1 Examples of reported bioactive indolo[2,3-b]quinoxaline derivatives.

image file: c5ra16727b-f2.tif
Fig. 2 New polynuclear fused N-heteroarenes (A) and its retrosynthetic analysis.

While various polynuclear fused N-heteroarenes are known in the literature4 molecules represented by A are unknown. It was therefore necessary to develop a suitable and general synthetic route for accessing molecules designed based on A. A retrosynthetic analysis of compound A revealed that its synthesis can be achieved via a 2-(1H-indol-3-yl)quinoxaline species B which in turn could be accessed from an indole derivative C (Fig. 2). While this route appeared to be feasible the major challenging issues however emerged as if conversion of B to A could be performed (i) with high efficiency (considering unknown reactivity of B towards the reactants employed), (ii) under metal catalyst free conditions, (iii) via a single-step method that is common and general for X = NR2, S, O etc. (Fig. 1). We envisaged that both the leaving groups of B could be displaced by a single nucleophile in a single step under appropriate reaction conditions to afford A. Herein we report our preliminary results on a catalyst, ligand and solvent free greener synthesis of A or 3 from 1 (Scheme 1).


image file: c5ra16727b-s1.tif
Scheme 1 Catalyst, ligand and solvent free synthesis of compound 3.

The key starting material 1 was prepared from indolin-2-one (4) that was converted to 5 (Scheme 2).5 The quinoxaline ring was constructed using the oxo-ester side chain of 5 following a similar procedure reported earlier6 to give 6. The chlorination of 6 afforded 1 that was either used directly (or after N-methylation) for the next step. The Pd-catalyzed double N-arylation of primary amines with 2,2′-dihalobiphenyl has become a powerful method for the construction of central 5-membered pyrrole ring of various carbazole derivatives.7 The methodology has been used for the elegant synthesis of several carbazole based alkaloids or natural products. We took inspiration from these works and decided to use a similar approach i.e. a double heteroarylation strategy for our synthesis. Accordingly, the compound 1a was reacted with amine 2a under various conditions (Table 1). Initially, several combinations of a Pd catalyst [e.g. Pd(OAc)2, Pd2(dba)3 and PdCl2] and a ligand (e.g. xantphos or BINAP) were used for the coupling of 1a with 2a at 80–100 °C depending on the solvent used e.g. 1,4-dioxane, DMF, toluene and MeCN (entries 1–8, Table 1). Generally, Cs2CO3 was used as a base in most of these cases. While the reaction proceeded in all these cases the yield of desired product 3a was not satisfactory except in two cases (entries 2 & 3, Table 1) and was poor when Et3N was used as a base (entry 5, Table 1). We then performed the reaction in the absence of any Pd-catalyst and ligands (entries 6–13, Table 1). To our surprise, the product yield was improved significantly in these cases. Change of base from Cs2CO3 to K2CO3 or DBU did not affect the yield of 3a dramatically (entries 14 & 15, Table 1) whereas Et3N once again found to be an inferior base in the present reaction (entry 16, Table 1). Interestingly, the product yield was continued to increase when the reaction was performed in the absence of any base (entries 17 & 18, Table 1) and finally in the absence of any solvent (entry 19, Table 1). Indeed the reaction was completed within 6 h in these cases affording 3a in 83–87% yield. Though it required marginally higher reaction temperature, we were delighted particularly with the catalyst, ligand and solvent free method (entry 19, Table 1) as this approach not only avoids the environmental hazard but also reduce the cost. Moreover, the product 3a was isolated in pure form without performing any chromatographic purification process [i.e. after completion of the reaction, the mixture was cooled to room temperature, diluted with cold water, filtered, and the solid obtained was titrated with methyl t-butyl ether (MTBE), see ESI]. Thus the condition of entry 19 of Table 1 was appeared to be optimal and used for further study.


image file: c5ra16727b-s2.tif
Scheme 2 Preparation of starting material 1.
Table 1 Reaction of 1a with 2a under various conditionsa

image file: c5ra16727b-u1.tif

Entry Catalyst/ligand Base Solvent %Yieldb
a Reaction conditions: 1a (1.0 mmol), amine 2a (1.1 mmol) and a base (3 mmol) at 80–100 °C for 8 h.b Isolated yield.c The reaction was performed for 6 h.d The reaction was performed at 135 ± 5 °C.
1 Pd(OAc)2/xantphos Cs2CO3 1,4-Dioxane 40
2 Pd(OAc)2/BINAP Cs2CO3 1,4-Dioxane 62
3 Pd(OAc)2/BINAP Cs2CO3 1,4-Dioxane 60
4 Pd2(dba)3/BINAP Cs2CO3 1,4-Dioxane 50
5 Pd(OAc)2/BINAP Et3N 1,4-Dioxane 5
6 PdCl2/BINAP Cs2CO3 DMF 10
7 Pd(OAc)2/BINAP Cs2CO3 Toluene 30
8 Pd(OAc)2/BINAP Cs2CO3 MeCN 10
9 Cs2CO3 1,4-Dioxane 50
10 Cs2CO3 DMF 75
11 Cs2CO3 DMSO 70
12 Cs2CO3 o-Xylene 65
13 Cs2CO3 NMP 76
14 K2CO3 DMF 68
15 DBU Toluene 69
16 Et3N DMF 23
17 DMF 83c
18 NMP 82c
19 87c,d


To test the generality and scope of this method the optimized reaction conditions were applied to a variety of substrates e.g. 1a, b and 2a–o (Table 2). Thus amines containing aliphatic and aromatic side chain or functional groups like ether, hydroxyl etc. or a chiral center in the side chain were examined. The reaction proceeded well in all these cases affording the desired products in good to excellent yields (entries 1–12, Table 2). The reaction also proceeded well with other N, O and S nucleophiles when the reaction time was shorter (entries 13–17, Table 2). Thus, indole fused with furo- and thieno[2,3-b]quinoxalines (3m, 3n, 3p and 3q) were prepared by reacting 1a, b with NaOH and Na2S separately. All these reactions were performed under open air as the process was not sensitive towards aerial oxygen or moisture. Moreover, NaCl or HCl (that can be neutralized by NaOH to harmless NaCl) being the byproduct in these reactions all the products were isolated in pure form after treating with water followed by titration with MTBE (see ESI). Notably, the Pd-based strategy for double arylation7 (leading to carbazoles) was successful only with amines and the use of O- or S- reactants is not common.8a Though a different strategy has been reported8b,c for the double arylation of S- reactants (leading to dibenzo[b,d]thiophene derivatives) involving the sequential use of n-BuLi followed by S2Cl2 (as sulfur source) none is known for double arylation of oxygen reactants leading to dibenzo[b,d]furan derivatives. Moreover, all these reactions required the use of an inert or anhydrous atmosphere. Thus our strategy presented here appeared to be a general one as all N, O and S nucleophiles could be reacted with 1 under a common reaction condition. To test the scale-up potential of this method the reaction of 1a with 2a (cf. entry 19, Table 1) was performed in g scale [i.e. 1.57 g (∼5 mmol) of 1a and 5.1 mmol of 2a] when 3a was isolated in 93% yield.

Table 2 Synthesis of indole fused pyrrolo-, furo- and thieno[2,3-b]quinoxalines (3)a

image file: c5ra16727b-u2.tif

Entry Compd (1), R1 = Nucleophile (2), X, Y, Z = T (h) Product (3) Yieldb (%)
a The reaction was carried out using 1 (1.0 mmol), and 2 (1.1 mmol) at 135 ± 5 °C.b Isolated yield.
1 1a; H 2a; PhCH2N, H, H 6 3a 87
2 1a 2b; Ph(CH2)2N, H, H 5 3b 89
3 1a 2c; (pyridin-2-yl)CH2N, H, H 6.5 3c 85
4 1a 2d; EtO(CH2)3N, H, H 5 3d 86
5 1a 2e; p-MeOC6H4CH2N, H, H 5 3e 87
6 1a 2f; MeO(CH2)3N, H, H 5 3f 87
7 1a 2g; Me(CH2)5N, H, H 5 3g 85
8 1a image file: c5ra16727b-u3.tif 9 3h 78
9 1a 2i; n-BuN, H, H 5 3i 80
10 1a 2j; 3,4-di-MeOC6H3(CH2)2N, H, H 5 3j 82
11 1a 2k; HO(CH2)2N, H, H 4 3k 78
12 1a 2l; 3,5-di-MeC6H3CH2N, H, H 7.5 3l 79
13 1a 2m; S, Na, Na 1 3m 91
14 1a 2n; O, Na, H 2 3n 67
15 1a 2o; NH2N, H, H 1.5 3o 85
16 1b; Me 2n 1.5 3p 70
17 1b 2m 0.5 3q 91


Mechanistically, the reaction may follow either “path a” or “path b” (Scheme 3). The path a involve a nucleophilic attack on the chloro group bearing C-2 of the quinoxaline ring to give E-1 whereas path b involve a similar attack on the chloro group bearing C-2 of the indole ring leading to E-2. Both E-1 and E-2 can undergo a second nucleophilic attack on its [double bond, length as m-dash]C–Cl moiety in an intramolecular fashion to afford the product 3.9a To gain evidence on which path was actually followed we revisited the reaction of 1a with 2a under various conditions. This allowed us to isolate an intermediate (4) in 53% yield along with 3a when the reaction was performed at 120 °C and stopped after 3 h (Scheme 4). While the initial spectral/analytical data indicated compound 4 as a monochloro derivative [(HRMS: m/z [M + 1] calcd for C23H18N4Cl (M + H): 385.1220; found: 385.1207) that was formed after displacing one of the two chloro groups of 1a by 2a] two alternative structures i.e. 4A and 4B (Fig. 3) were possible in this case. However, the structure of 4 was confirmed as 4A that showed single NOE interaction between NH and C(7)–H of indole ring (Fig. 3). Notably, two NOE interactions were expected in case of 4B. Finally, the intermediate 4 afforded 3a when heated at 130 °C for 3 h indicating its intermediacy in the present reaction. It is to be mentioned that compound 4 did not react with 2a when treated with 2a in a separate experiment but afforded 3a indicating intramolecular cyclization of 4 leading to 3a was preferred over other reaction.9b Thus, all these observations suggested that the reaction followed path a rather than path b.


image file: c5ra16727b-s3.tif
Scheme 3 Proposed reaction mechanism.

image file: c5ra16727b-s4.tif
Scheme 4 The preparation of intermediate 4 and its conversion to 3a.

image file: c5ra16727b-f3.tif
Fig. 3 Alternative structures and NOE spectra of compound 4.

In view of known anti-tumor/anti-cancer properties of related indolo[2,3-b]quinoxaline derivatives,2 all the synthesized compounds were evaluated for their ability to inhibit the growth of cancer cells. These compounds were tested at 10 μM against three cancer cells e.g. A549 (lung), MCF-7 (breast) and TZM-BL (cervical) using the sulphorhodamine B (SRB) assay10a,b with gemcitabine10c as a reference compound. Among these compounds, 3a–l showed >90% inhibition against lung cancer cells (comparable to gemcitabine's 90% inhibition), >75% inhibition against breast cancer cells (gemcitabine 49%), and >60% against cervical cancer cells (gemcitabine 90%). Moreover, these compounds did not showed significant effect on normal HEK 293T cells (10–15% inhibition vs. gemcitabine's 25%) indicating their selectivity toward cancer cells.

In conclusion, a straightforward yet innovative method has been developed for the double heteroarylation of N, O and S nucleophiles leading towards the synthesis of polynuclear N-heteroarenes. This operationally simple, general, greener and cost-effective method can be performed under open air and is amenable for scale-up. The methodology afforded a library of novel compounds containing indole ring fused with pyrrolo-, furo- and thieno[2,3-b]quinoxaline moiety without the need of chromatographic purification. Several of these compounds showed promising and selective cytotoxicities against cancer cells. Overall, being unprecedented the present strategy of catalyst/ligand/solvent free double heteroarylation of N, O and S nucleophiles could be useful in accessing a wide range of novel bioactive molecules of medicinal importance.

Acknowledgements

SPN thanks to Dr Vilas Dahanukar, Dr Rama Mohan, Dr K. B. Shiva Kumar and the analytical group of CPS-DRL for support.

Notes and references

  1. A. Lauria, C. Patella, G. Dattolo and A. M. Almerico, J. Med. Chem., 2008, 51, 2037 CrossRef CAS PubMed.
  2. (a) J. Harmenberg, A. Gr, T. Malmfors, J. Bergman, B. Wahren and S. Cox, Antiviral Res., 1991, 15, 193 CrossRef CAS; (b) K. Hirata, J. Araya, S. Nakaike, K. Kitamura and T. Ishida, Chem. Pharm. Bull., 2001, 49, 44 CrossRef CAS; (c) S. T. Hazeldine, L. Polin, J. Kushner, K. White, T. H. Corbett and J. P. Horwitz, Bioorg. Med. Chem., 2006, 14, 2462 CrossRef CAS PubMed; (d) For a review, see: N. S. Moorthy, E. Manivannan, C. Karthikeyan and P. Trivedi, Mini-Rev. Med. Chem., 2013, 13, 1415 CrossRef.
  3. (a) K. S. Kumar, D. Rambabu, S. Sandra, R. Kapavarapu, G. R. Krishna, M. V. B. Rao, K. Chatti, C. M. Reddy, P. Misra and M. Pal, Bioorg. Med. Chem., 2012, 20, 1711 CrossRef CAS PubMed; (b) K. S. Kumar, D. Rambabu, B. Prasad, M. Mujahid, G. R. Krishna, M. V. B. Rao, C. M. Reddy, G. R. Vanaja, A. M. Kalle and M. Pal, Org. Biomol. Chem., 2012, 10, 4774 RSC; (c) A. Nakhi, S. Archana, G. P. K. Seerapu, K. S. Chennubhotla, K. L. Kumar, P. Kulkarni, D. Haldar and M. Pal, Chem. Commun., 2013, 49, 6268 RSC; (d) A. Nakhi, Md. S. Rahman, G. P. K. Seerapu, R. K. Banote, K. L. Kumar, P. Kulkarni, D. Haldar and M. Pal, Org. Biomol. Chem., 2013, 11, 4930 RSC; (e) P. V. Babu, S. Mukherjee, G. S. Deora, K. S. Chennubhotla, R. Medisetti, S. Yellanki, P. Kulkarni, S. Sripelly, K. V. L. Parsa, K. Chatti, K. Mukkanti and M. Pal, Org. Biomol. Chem., 2013, 11, 6680 RSC; (f) R. Sunke, P. V. Babu, S. Yellanki, R. Medishetti, P. Kulkarni and M. Pal, Org. Biomol. Chem., 2014, 12, 6800 RSC; (g) S. K. Kolli, A. Nakhi, R. Medishetti, S. Yellanki, P. Kulkarni, R. R. Raju and M. Pal, Bioorg. Med. Chem. Lett., 2014, 24, 4460 CrossRef CAS PubMed; (h) S. K. Kolli, A. Nakhi, S. Archana, M. Saridena, G. S. Deora, S. Yellanki, R. Medisetti, P. Kulkarni, R. R. Raju and M. Pal, Eur. J. Med. Chem., 2014, 63, 270 CrossRef PubMed; (i) R. Sunke, V. Kumar, E. V. V. S. Ramarao, R. Bankala, K. V. L. Parsa and M. Pal, RSC Adv., 2015, 5, 70604 RSC.
  4. Comprehensive heterocyclic chemistry, ed. A. R. Katritzky and C. W. Rees, Pergamon Press, Ltd, Headington Hill Hall, Oxford OX3 OBW, England, 1984, vol. 1–8 Search PubMed.
  5. W. Fröhner, B. Monse, T. M. Braxmeier, L. Casiraghi, H. Sahagún and P. Seneci, Org. Lett., 2005, 7, 4573 CrossRef PubMed.
  6. R. Sakhuja, S. M. A. Shakoor, S. Kumari and A. Kumar, J. Heterocycl. Chem., 2015, 52, 773 CrossRef CAS PubMed.
  7. For selected references, see: (a) K. Nozaki, K. Takahashi, K. Nakano, T. Hiyama, H.-Z. Tang, M. Fujiki, S. Yamaguchi and K. Tamao, Angew. Chem., Int. Ed., 2003, 42, 2051 CrossRef CAS PubMed; (b) A. Kuwahara, K. Nakano and K. Nozaki, J. Org. Chem., 2005, 70, 413 CrossRef CAS PubMed; (c) A. Ueno, T. Kitawaki and N. Chida, Org. Lett., 2008, 10, 1999 CrossRef CAS PubMed; (d) T. Kitawaki, Y. Hayashi, A. Ueno and N. Chida, Tetrahedron, 2006, 62, 6792 CrossRef CAS PubMed; (e) T. Kitawaki, Y. Hayashi and N. Chida, Heterocycles, 2005, 65, 1561 CrossRef CAS; (f) Y. Zhou and J. G. Verkade, Adv. Synth. Catal., 2010, 352, 616 CrossRef CAS PubMed; (g) For synthesis of azepines, see: ; (h) X. Zhang, Y. Yang and Y. Liang, Tetrahedron Lett., 2012, 53, 6406 CrossRef CAS PubMed; (i) N. Božinović, I. Opsenica and B. A. Šolaja, Synlett, 2013, 24, 49 Search PubMed.
  8. (a) Only two examples on Pd-catalyzed double arylation of sulfur leading to thiepine derivatives in low to moderate yield has been reported, see ref. 7i; (b) K. Geramita, J. McBee and T. D. Tilley, J. Org. Chem., 2009, 74, 820 CrossRef CAS PubMed; (c) G. Delogu, D. Fabbri, M. A. Dettori, A. Forni and G. Casalone, Tetrahedron: Asymmetry, 2001, 12, 1451 CrossRef CAS.
  9. (a) Since products 3a–l and 3o were never isolated as a HCl salt after usual work-up, it appeared that the HCl generated during the reaction in most cases formed a weak salt with 3 which however was dissociated during aqueous work-up. This was supported by the acidic nature of aqueous filtrate collected that was later neutralized by dil NaOH solution; (b) The reaction of 1a (1 mmol) with excess of 2a (upto 10 mmol) also afforded 3a but no di-benzylamino substituted product [i.e. N-benzyl-3-(2-(benzylamino)-1H-indol-3-yl)quinoxalin-2-amine] supported this observation.
  10. (a) L. V. Rubinstein, R. H. Shoemaker, K. D. Paull, R. M. Simon, S. Tosini, P. Skehan, D. A. Scudiero, A. Monks and M. R. Boyd, J. Natl. Cancer Inst., 1990, 82, 1113 CrossRef CAS PubMed; (b) P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney and M. R. Boyd, J. Natl. Cancer Inst., 1990, 82, 1107 CrossRef CAS PubMed; (c) E. Chu and V. T. Devita, Physicians' Cancer Chemotherapy Drug Manual, Jones & Bartlett, 2007 Search PubMed.

Footnote

Electronic supplementary information (ESI) available: Experimental procedures, spectral data for all new compounds, and copies of spectra. See DOI: 10.1039/c5ra16727b

This journal is © The Royal Society of Chemistry 2015